Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor antagonist, and α2-macroglobulin
American Journal of Veterinary Research · 01.04.2025 · 86 (4)
DOI: 10.2460/ajvr.24.11.0363 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, erschienen am 01.04.2025. Verfasst von Dhvani Barot und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Studies-New Bolton Center, University of Pennsylvania, Kennett Square, PA. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Interleukin 1 Receptor Antagonist Protein, alpha-Macroglobulins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Quantify the concentration of α 2 -macroglobulin (A2M), immunomodulatory cytokines, and TGF-β1 factors in 4 commercially available autologous blood-based products including conditioned A2M (CA2M; Alpha2EQ; Astaria Global), autologous protein solution (APS; Pro-Stride; Zoetis), platelet-rich plasma (PRP; Restigen; Zoetis), and autologous conditioned plasma (ACP; Arthrex ACP). We hypothesized that CA2M would have higher concentrations of A2M and lower concentrations of cytokines and growth factors compared to APS, PRP, and ACP.
Methods
Blood was obtained from 6 healthy, adult horses and processed into CA2M, APS, PRP, and ACP. The concentration of immunomodulatory cytokines, including IL-1β, IL-4, IL-6, IL-10, IL-17a, and TNF-α, and the concentration of the growth factor TGF-β1 were quantified using immunoassays. The concentration of the IL-1 receptor antagonist was quantified using ELISA. The concentration of A2M was quantified using mass spectrometry.
Results
No differences in the concentrations of IL-1β, IL-4, IL-6, IL-10, and IL-17a were found. Median TGF-β1 was significantly higher in APS (10,801 pg/mL; P < .05), PRP (6,219 pg/mL; P < .05), and ACP (5,263 pg/mL; P < .05) compared to CA2M (2,090 pg/mL). The IL-1 receptor antagonist was significantly higher in APS (58.78 ng/mL) and PRP (40.45 ng/mL). Median A2M concentration was significantly higher in APS (4.08 mg/mL; P < .001) compared to CA2M (1.99 mg/mL).
Conclusions
Autologous blood-based products have notably different immunomodulatory and growth factor profiles. These differences likely reflect variable concentrations of platelets and WBCs, as well as processing methods. Clinical Relevance Equine veterinarians should be aware of the constituents of the different orthobiologics available before use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Studies-New Bolton Center, University of Pennsylvania, Kennett Square, PA.
- Bessemer Equine, Kennett Square, PA.
ORCID-Profile: Kyla F Ortved
Zitieren
APA
Barot, D., Usimaki, A., Linardi, R. L., Arensberg, C. M., & Ortved, K. F. (2025). Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor antagonist, and α2-macroglobulin. American Journal of Veterinary Research, 86(4). https://doi.org/10.2460/ajvr.24.11.0363
Vancouver
Barot D, Usimaki A, Linardi RL, Arensberg CM, Ortved KF. Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor antagonist, and α2-macroglobulin. American Journal of Veterinary Research. 2025;86(4). doi:10.2460/ajvr.24.11.0363
BibTeX
@article{Barot2025,
author = {Barot, Dhvani and Usimaki, Alexandra and Linardi, Renata L and Arensberg, Charles M and Ortved, Kyla F},
title = {Equine autologous blood-based products contain variable quantities of transforming growth factor-β1, interleukin-1 receptor antagonist, and α2-macroglobulin},
journal = {American Journal of Veterinary Research},
year = {2025},
volume = {86},
number = {4},
doi = {10.2460/ajvr.24.11.0363}
}
EUVIMED